Fortis Healthcare Ltd. (NSE: FORTIS, BSE: 532843) is a Gurugram, Haryana-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹58,283 Cr, it ranks #186 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 46 in Hospitals and Healthcare Centers. At ₹764.00 (as of 16 Nov 2026), the share price is 24.4% below its 52-week high of ₹1,010.10 and 8.4% above its 52-week low of ₹704.95. The share price is down 25.1% over one year and down 15.7% over three months.
| Current Price | ₹764.00 |
|---|---|
| Market Cap | ₹58,283 Cr |
| NSE Symbol | FORTIS |
| BSE Code | 532843 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 55.1 |
| Return on Equity | 11.01% |
| Return on Assets | 6.84% |
| 52-Week Range | ₹704.95 – ₹1,010.10 |
| 1-Year Price Change | -25.1% |
| 3-Month Price Change | -15.7% |
| Beta (1Y) | 0.46 |
| Dividend Yield | 0.13% |
| Headquarters | Gurugram, Haryana |
| Website | www.fortishealthcare.com |
| Revenue | ₹2,735 Cr |
|---|---|
| Net Profit | ₹320 Cr |
| Net Margin | 11.7% |
| EPS (Basic) | ₹4.14 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Fortis Healthcare Ltd. reported revenue of ₹2,735 Cr in Q2 FY27, up 17.3% from ₹2,331 Cr in Q2 FY26 and up 7.5% from ₹2,545 Cr in Q1 FY27. It posted a net profit of ₹320 Cr for the quarter, against a net profit of ₹325 Cr in Q2 FY26 (down 1.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,007 Cr (Q4 FY25) to ₹2,735 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,735 Cr | ₹320 Cr | 11.7% |
| Q1 FY27 | ₹2,545 Cr | ₹268 Cr | 10.5% |
| Q4 FY26 | ₹2,365 Cr | ₹265 Cr | 11.2% |
| Q3 FY26 | ₹2,265 Cr | ₹194 Cr | 8.6% |
| Q2 FY26 | ₹2,331 Cr | ₹325 Cr | 13.9% |
| Q1 FY26 | ₹2,167 Cr | ₹264 Cr | 12.2% |
| Q4 FY25 | ₹2,007 Cr | ₹188 Cr | 9.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 31.17% of Fortis Healthcare Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 54.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, and haematology areas. It also provides services in the areas of infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, organ transplant, rheumatology, thoracic surgery, transfusion medicine, urology, medical generics, endocrine surgery, and other support specialties, as well as treat infectious dise
1. Healthcare Services-This segment manages and operates a network of multi-specialty hospitals. 2. Diagnostics-This segment manages and operates a network of diagnostic centers. 3. Inter Segment-0 4. Un-Allocable Assets-0
1. Healthcare-85.2% 2. Diagnostics-16.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Dr. Agarwal's Health Care Limited | ₹17,568 Cr | 131.9 | 8.31% | ₹655 Cr | +9.3% |
Listed by market capitalisation. Ratios are shown for context only.
Fortis Healthcare Ltd. is trading at ₹764.00, with a market capitalisation of ₹58,283 Cr.
Fortis Healthcare Ltd. operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Fortis Healthcare Ltd. has a P/E of 55.1 and a return on equity of 11.01%.
Fortis Healthcare Ltd. is listed on the NSE under the symbol FORTIS and on the BSE under the scrip code 532843.
Fortis Healthcare Ltd.'s share price is down 25.1% over one year and down 15.7% over three months. Its 52-week range is ₹704.95 to ₹1,010.10.
In Q2 FY27, Fortis Healthcare Ltd. reported revenue of ₹2,735 Cr and net profit of ₹320 Cr, with basic EPS of ₹4.14 (consolidated, parsed from the company's exchange filing).
Fortis Healthcare Ltd. reported revenue of ₹2,735 Cr in Q2 FY27, up 17.3% from ₹2,331 Cr in Q2 FY26 and up 7.5% from ₹2,545 Cr in Q1 FY27.
Promoters held 31.17% of Fortis Healthcare Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.